Complete Filing Data
Addex Therapeutics Ltd. reported Profit Loss of $7.06 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Addex Therapeutics Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Profit Loss | $7.1M | -$10.6M | -$20.8M | -$15.4M | -$12.9M | -$14.8M | -$1.6M | -$3.3M |
| Other Comprehensive Income | -$412.9K | -$508.2K | $1.3M | $260.3K | -$237.6K | -$746.7K | -$375.7K | -$10.8K |
| Comprehensive Income | $6.6M | -$11.1M | -$19.5M | -$15.1M | -$13.1M | -$15.5M | -$2.0M | -$3.3M |
| Research And Development Expense | $854.3K | $1.2M | $8.2M | $12.8M | $10.4M | $12.5M | $4.9M | $2.6M |
| Profit Loss From Operating Activities | -$2.8M | -$2.2M | -$10.5M | -$15.5M | -$12.2M | -$14.6M | -$1.4M | -$3.2M |
| Profit Loss Before Tax | -$4.9M | -$2.5M | -$10.8M | -$15.4M | -$12.9M | -$14.8M | -$1.6M | -$3.3M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | $985.00 | -$2.0K | -$345.00 | -$295.00 | -$4.1K | -$838.00 | -$181.00 | -$871.00 |
| General And Administrative Expense | $2.3M | $2.7M | $3.7M | $5.8M | $5.7M | $5.0M | $3.2M | $1.1M |
| Revenue From Contracts With Customers | $404.1K | $1.6M | $1.4M | $2.9M | $3.6M | $2.8M | $6.0M | |
| Other Comprehensive Income Net Of Tax Gains Losses On Remeasurements Of Defined Benefit Plans | -$506.2K | $1.3M | $260.5K | -$233.5K | -$745.9K | -$375.5K | -$9.9K | |
| Income Tax Expense Continuing Operations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost Of Sale Of Pre Funded Warrants Equity | $136.3K | $301.8K | $849.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $3.3M | $3.9M | $7.0M | $20.5M | $18.7M | $31.5M | $31.5M | $2.6M | $1.4M |
| Property Plant And Equipment | $1.1K | $22.6K | $41.1K | $72.1K | $67.8K | $27.6K | $8.9K | $2.8K | |
| Rightofuse Assets | $41.6K | $330.3K | $357.6K | $470.0K | $565.3K | $543.3K | |||
| Cash Flows From Used In Operating Activities | -$5.4M | -$8.0M | -$16.4M | -$14.7M | -$12.2M | -$9.5M | $1.8M | -$2.1M | |
| Cash Flows From Used In Financing Activities | $104.9K | $5.3M | $3.1M | $16.4M | $46.4K | -$463.7K | $37.4M | $3.4M | |
| Adjustments For Increase Decrease In Trade And Other Payables | -$1.1M | -$613.2K | -$427.4K | $883.8K | -$1.6M | $2.0M | $1.1M | -$212.1K | |
| Adjustments For Decrease Increase In Trade And Other Receivables | $93.1K | $306.5K | -$252.1K | -$96.4K | $49.7K | $155.0K | -$77.1K | -$83.2K | |
| Adjustments For Decrease Increase In Other Financial Assets | -$5.6K | $2.3K | $14.0K | $47.8K | -$51.0K | -$6.0K | $3.3K | -$5.0K | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $1.3K | $6.8K | $581.00 | $31.5K | $59.4K | $28.5K | $9.1K | $697.00 | |
| Cash Flows From Used In Investing Activities | $4.6M | -$6.8K | $3.0K | -$30.3K | -$59.4K | -$43.3K | -$56.4K | -$697.00 | |
| Trade And Other Current Receivables | $15.5K | $110.4K | $416.9K | $164.8K | $68.4K | $118.0K | $273.0K | ||
| Trade And Other Current Payables | $794.8K | $2.4M | $3.0M | $3.8M | $2.5M | $4.2M | $2.1M | ||
| Retained Earnings | -$353.4M | -$360.4M | -$349.9M | -$329.1M | -$313.7M | -$300.8M | -$286.1M | ||
| Other Current Financial Assets | $6.5K | $848.00 | $3.2K | $17.1K | $64.9K | $14.0K | $8.0K | ||
| Noncurrent Liabilities | $198.9K | $603.1K | $87.0K | $1.5M | $2.0M | $1.8M | $639.4K | ||
| Noncurrent Financial Assets | $7.1K | $54.3K | $54.4K | $57.9K | $59.1K | $68.9K | $54.4K | ||
| Noncurrent Assets | $7.1M | $407.3K | $453.1K | $600.0K | $692.2K | $639.9K | $63.3K | ||
| Equity And Liabilities | $10.7M | $4.6M | $8.3M | $22.5M | $20.2M | $33.0M | $42.2M | ||
| Current Liabilities | $802.1K | $2.9M | $3.3M | $4.1M | $3.6M | $5.7M | $2.3M | ||
| Current Assets | $3.5M | $4.2M | $7.8M | $21.9M | $19.5M | $32.4M | $42.2M | ||
| Assets | $10.7M | $4.6M | $8.3M | $22.5M | $20.2M | $33.0M | $42.2M | ||
| Noncurrent Lease Liabilities | $34.7K | $70.4K | $87.0K | $194.3K | $258.8K | $177.2K | |||
| Current Lease Liabilities | $7.3K | $274.0K | $286.1K | $287.7K | $308.6K | $373.0K | |||
| Noncurrent Recognised Liabilities Defined Benefit Plan | $164.3K | $443.5K | $1.3M | $1.7M | $1.5M | $639.4K | |||
| Adjustments For Decrease Increase In Contract Assets | $40.9K | $140.5K | -$21.8K | -$159.6K | |||||
| Adjustments For Increase Decrease In Deferred Income Other Than Contract Liabilities | -$38.4K | $324.2K | -$86.5K | -$244.3K | $330.8K | ||||
| Other Equity Interest | $64.6M | $64.6M | $64.6M | ||||||
| Increase Decrease Through Sale Of Pre Funded Warrants Equity | $3.4M | $2.8M | $5.5M | ||||||
| Current Contract Assets | $40.9K | $181.4K | $159.6K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$623.4K | -$2.7M | -$13.3M | $1.7M | -$12.2M | -$10.0M | $39.1M | $1.2M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $99.7K | -$356.9K | -$196.2K | $122.5K | -$648.7K | -$144.3K | $10.5K | -$45.3K |
| Payments Of Lease Liabilities Classified As Financing Activities | $73.7K | $281.8K | $288.1K | $309.6K | $367.4K | $316.8K | ||
| Payments For Share Issue Costs | $1.7M | $272.0K | $61.2K | $3.0M | $25.6K | |||
| Proceeds From Sale Purchase Of Treasury Shares | 3.8M | 720.0K | 6.0K | -5.4K | 3.4M | |||
| Proceeds From Sale Of Treasury Shares Under Liquidity And Sale Agency Agreement | 240.9K | 1.2M | 451.0K | 33.2K | 720.0K | |||
| Proceeds From Sale Of Treasury Shares Shelf Registration | 1.2M | 1.2M | 3.8M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Diluted Earnings Loss Per Share | $0.07 | $-0.14 | $-0.46 | $-0.45 | $-0.48 | $-0.56 |
| Basic Earnings Loss Per Share | $0.07 | $-0.14 | $-0.46 | $-0.45 | $-0.48 | $-0.56 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Net Sales Purchases Of Treasury Shares Under Liquidity Agreement | 5.6K | -2.3K | -14.0K | -47.8K | -29.0K | 6.0K | -5.2K | 6.0K |
| Increase Decrease Through Sharebased Payment Transactions | $1.7M | $1.8M | $3.7M | $1.2M | $1.2M | $1.7M | $2.3M | $800.2K |
| Share Issue Related Cost | $7.0K | $30.8K | $288.1K | $1.9M | $1.8M | $170.4K | $3.0M | $25.6K |
| Operating Expense | $3.2M | $3.9M | $12.0M | $18.7M | $16.1M | $17.4M | $8.1M | $3.7M |
| Finance Income Cost | $23.0K | -$257.2K | -$263.1K | $154.0K | -$615.3K | -$176.4K | -$220.2K | -$45.4K |
| Finance Costs | $3.5K | $321.2K | $292.3K | $63.0K | $650.6K | $213.3K | $220.2K | $45.4K |
| Other Income | $5.9K | $4.2K | $22.5K | $237.0K | $266.3K | $70.8K | $658.8K | $499.9K |
| Issued Capital | $1.8M | $1.8M | $1.2M | $49.3M | $32.8M | $32.8M | $28.6M | |
| Finance Income | $26.6K | $64.0K | $29.3K | $217.0K | $35.3K | $36.9K | ||
| Interest Paid Classified As Financing Activities | $9.2K | $21.6K | $48.9K | $63.0K | $69.5K | $128.5K | $134.3K | $171.00 |
| Adjustments For Sharebased Payments | $503.0K | $1.8M | $3.7M | $1.2M | $1.2M | $1.7M | $2.3M | $800.2K |
| Adjustments For Provisions | -$95.2K | -$62.6K | -$11.4K | -$150.5K | -$22.7K | $96.5K | $20.0K | $19.5K |
| Adjustments For Depreciation Expense | $260.1K | $306.0K | $323.1K | $347.6K | $378.8K | $333.8K | $2.9K | $15.2K |
| Interest Received Classified As Financing Activities | $9.2K | $64.0K | $29.3K | $5.3K | $35.3K | $36.9K | ||
| Share Premium | $266.4M | $266.2M | $269.5M | $284.0M | $286.9M | $286.4M | $286.5M | |
| Adjustments For Finance Income Cost | $99.6K | -$312.6K | -$215.5K | $132.1K | -$686.9K | -$234.7K | ||
| Adjustments For Decrease Increase In Prepaid Expenses | -$164.3K | $53.4K | $845.0K | -$617.0K | $221.7K | -$520.7K | ||
| Settlement Of Supplier Invoices Through Treasury Shares | 165.0K | 285.7K | 289.2K | 208.1K | 261.3K | |||
| Treasury Shares | 869.7K | 909.6K | 6.3M | 11.7M | 6.1M | |||
| Other Reserves | $31.1M | $29.8M | $25.8M | $24.4M | $14.7M | |||
| Current Prepayments | $169.6K | $217.0K | $270.4K | $1.1M | $720.1K | $199.4K | ||
| Adjustments For Services Paid In Shares | 165.0K | 285.7K | 289.2K | 208.1K | 258.9K | |||
| Issue Of Shares Third Parties | 10.1M | 11.5M | ||||||
| Costs Paid On Sales Of Treasury Shares Shelf Registration | 24.0K | 39.1K | 304.0K | 389.9K | ||||
| Sale Or Issue Under Shelf Registration | $1.2M | $1.2M | $3.8M | |||||
| Shares Issue Of Shelf Registration Related Cost | 36.7K | 114.8K | 581.8K | |||||
| Costs Paid On Sale Of Treasury Shares Under Sale Agency Agreement | 1.8K | 8.9K | 3.5K | 332.00 | ||||
| Costs Paid On Sale Of Pre Funded Warrants | $141.8K | $576.1K | $569.2K | |||||
| Other Net Sale Of Treasury Shares | 80.9K | 749.1K |
Most recent annual filing with the SEC: May 15, 2025
Data sourced from SEC EDGAR public filings as of August 8, 2026.